BioCentriq
BioCentriq (dba Made Scientific) is a U.S. cell therapy CDMO offering GMP development and manufacturing services across T Cells, NK Cells, HSCs, MSCs, iPSCs, and TILs from pre-clinical through commercial scale, serving pharma and biotech developers from its Princeton, NJ facility.
- Company typePrivate
- Founded2019
- HeadquartersNewark, United States
- Headcount101–250
- GTM typeB2B
- OfferingServices
What BioCentriq does
BioCentriq (operating as Made Scientific) is a cell therapy contract development and manufacturing organization (CDMO) headquartered in Newark, New Jersey with its main 60,000 ft² Development Center of Excellence in Princeton, NJ. The company supports therapeutic developers and pharmaceutical/biotech firms across the full cell therapy lifecycle — pre-clinical support, Phase I-III clinical trials, and commercial enablement — across multiple cell types including T Cells, NK Cells, HSCs, MSCs, iPSCs, TILs, and Exosomes. Service modules span process and analytical development, GMP and non-GMP cell banking and drug product manufacture, GMP aseptic fill and finish, quality control lot release and stability studies, regulatory consulting for IND/BLA submissions, and workforce development through the Made Scientific Foundry™ program.
The underlying technology stack combines GMP-compliant manufacturing infrastructure (five ISO 7/Grade B cleanrooms, BSL-2 compliance, in-house QC labs, cryo-storage and cold-chain management) with proprietary platform technologies including MadeFast™ with RapidCell™, a single-step CAR-T manufacturing platform designed to accelerate time-to-clinic, and a viral clearance platform for AAV gene therapy co-developed with Cytiva under NIIMBL funding. The Princeton expansion adds 12,000 ft² of GMP cleanroom space with high-throughput suites featuring AI-driven robotic automation, targeting approximately 5,000 additional manufacturing batches per year at full capacity.
BioCentriq generates revenue through project-based CDMO contracts under three engagement models: traditional and dedicated service for all clients, hybrid client-in-plant operations for mid-to-late stage programs, and custom build-outs for late-stage and commercial clients, with multi-year dedicated capacity contracts available to secure supply chains. Pricing is quote-based and not publicly disclosed. The company closed a $29.2 million Series A in January 2024 to fund facility expansion, advanced technology investment, and team growth, and is led by CEO Syed Husain alongside VP of Development David Smith.
BioCentriq firmographics
Firmographics- Name
- BioCentriq
- Legal name
- Made Scientific
- Website
- https://biocentriq.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- BioCentriq (dba Made Scientific) is a U.S. cell therapy CDMO offering GMP development and manufacturing services across T Cells, NK Cells, HSCs, MSCs, iPSCs, and TILs from pre-clinical through commercial scale, serving pharma and biotech developers from its Princeton, NJ facility.
- Ownership category
- akta.pro rank
BioCentriq industry classification
Industry- Product category
- Cell Therapy Contract Development & Manufacturing
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)
- akta.pro primary industry
- Cell Therapy CDMO (Autologous/Allogeneic Manufacturing) (HLAGAGAA)
- akta.pro secondary industries
- Cell Therapy CDMO (HLAGABAD), Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH), Gene Therapy Vector Manufacturing & CDMO Services (HLAAACAJ)
Keywords
Where BioCentriq is headquartered
LocationHeadquarters
- HQ city
- Newark
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
BioCentriq business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Infrastructure, Technology or R&D, Operations, Marketing or Sales, Supply Chain
Revenue model
- Contract Development and Manufacturing Services: Fee-for-service CDMO model providing cell therapy development and GMP manufacturing services to pharmaceutical and biotech companies. Revenue generated through project-based contracts for process development, GMP manufacturing, quality control testing, regulatory consulting, and workforce training.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Traditional & Dedicated Service - Turnkey solutions with platform processes or purpose-built technology transfer plus dedicated capacity models |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
BioCentriq product offering
Product offeringCore offering
BioCentriq (operating as Made Scientific) is a cell therapy Contract Development and Manufacturing Organization (CDMO) that provides end-to-end development, GMP manufacturing, and release services for cell therapies including T Cells, NK Cells, HSCs, MSCs, iPSCs, TILs, and Exosomes. Services span pre-clinical support through Phase I-III clinical trials and commercial enablement, with flexible engagement models including traditional dedicated service, hybrid client-in-plant operations, and custom build-outs.
Product overview
Made Scientific is a cell therapy CDMO (Contract Development and Manufacturing Organization) offering a unified platform of manufacturing solutions. The core offering includes Cell Therapy CDMO Services supporting T Cells, NK Cells, HSCs, MSCs, iPSCs, TILs, and Exosomes from pre-clinical through commercial stages. Supporting service modules include Process & Analytical Development, GMP and Non-GMP Manufacturing, GMP Aseptic Fill & Finish, Quality Control Testing & Stability Studies, Regulatory Consulting, and Workforce Development & Training via Made Scientific Foundry™. The company also provides Ready-Made Platforms for fast-track IND filings and MadeFast™ with RapidCell™ as a proprietary single-step CAR-T manufacturing platform. Partnership models include Traditional & Dedicated Service, Hybrid Client-In-Plant Operations, and Custom Build-outs & Partnerships.
Differentiator
Problem solved
Functional benefit
Brands
- MadeFast™: Single-step CAR-T manufacturing platform with RapidCell™ technology
- Made Foundry™
- RapidCell™
Products and services
- Cell Therapy CDMO Services
Quantifiable outcome
- Approximately 5,000 additional manufacturing batches per year at full capacity from expansion
Companies that use BioCentriq
Customer profileSegments3 records
Ideal customer profiles2 records
BioCentriq technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
BioCentriq partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- CytivacoreBioCentriq and Cytiva collaborated on a NIIMBL-funded project to develop a viral clearance platform for AAV manufacturing. The partnership aimed to accelerate gene therapy development through improved viral safety testing and clearance methodologies.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
BioCentriq competitors and assessment
Company assessmentBroad incumbents
- Samsung Biologics: Samsung Biologics is expanding into cell and gene therapy CDMO services alongside its large-scale biologics manufacturing. As a broad incumbent with deep capital resources, it represents a competitive threat as the cell therapy outsourcing market matures.
- Lonza Cell & Gene Technologies: Lonza is one of the largest global CDMOs with a dedicated cell and gene therapy business offering process development, GMP manufacturing, and viral vector production. It is a broad incumbent serving overlapping pharmaceutical and biotech clients with comparable services across cell therapy modalities.
- Thermo Fisher Scientific (Patheon / Brammer Bio): Thermo Fisher provides cell therapy manufacturing services through its pharma services business (including legacy Brammer Bio viral vector capabilities). As a broad incumbent with global infrastructure, it competes for large pharma cell therapy outsourcing contracts.
- WuXi Advanced Therapies Unit: WuXi Advanced Therapies provides cell and gene therapy development, viral vector manufacturing, and GMP services globally. Its scale and broad service portfolio position it as a major competing CDMO for cell therapy developers.
- Charles River Laboratories: Charles River provides cell therapy CDMO services, manufacturing support, and related safety/QC testing. Its broad life sciences footprint and integrated services make it a key comparator in the cell therapy manufacturing space.
- Catalent (Cell & Gene Therapy): Catalent's Cell & Gene Therapy division provides process development, manufacturing, and fill-finish for cell therapies including CAR-T and viral vectors. As a broad incumbent with multi-site capacity, it competes for the same enterprise pharma and biotech clients as BioCentriq.
Emerging players
- Vineti: Vineti provides cell therapy supply chain orchestration software and related services. While not a direct manufacturing peer, it is an emerging ecosystem participant addressing adjacent workflow needs of cell therapy developers served by BioCentriq.
- Cellares: Cellares offers automated, high-throughput cell therapy manufacturing through its Cell Shuttle platform. It is an emerging player pursuing the same automation-driven throughput advantage that BioCentriq targets with its AI-driven robotic automation expansion.
Direct peers
- AGC Biologics: AGC Biologics is a mid-sized global CDMO offering cell and gene therapy process development and GMP manufacturing. It is comparable to BioCentriq in scale and service scope, competing for similar biotech and pharmaceutical clients across cell modalities.
- Miltenyi Biotec: Miltenyi Biotec offers cell therapy manufacturing services alongside its core cell separation instruments and reagents. It is directly comparable in cell therapy modalities served and in serving biotech developers needing GMP capacity.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
BioCentriq social profiles
Digital presenceBioCentriq financial estimates
Financial estimateRevenue estimate
Valuation estimate
BioCentriq leadership team
Management profileNumber of profiles
Profiles2 records
BioCentriq funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BioCentriq M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BioCentriq
What does BioCentriq do?
BioCentriq (operating as Made Scientific) is a cell therapy Contract Development and Manufacturing Organization (CDMO) that provides end-to-end development, GMP manufacturing, and release services for cell therapies including T Cells, NK Cells, HSCs, MSCs, iPSCs, TILs, and Exosomes. Services span pre-clinical support through Phase I-III clinical trials and commercial enablement, with flexible engagement models including traditional dedicated service, hybrid client-in-plant operations, and custom build-outs.
Is BioCentriq a public or private company?
BioCentriq is a private company. It is classified as venture growth investor backed and is currently operating.
When was BioCentriq founded?
BioCentriq was founded in 2019. It employs 101 to 250 people.
Where is BioCentriq based?
BioCentriq is headquartered in Newark, United States, in the North America region.
How does BioCentriq make money?
One revenue line is on record: contract Development and Manufacturing Services.
Who are BioCentriq's main competitors?
Broad incumbents on record are Samsung Biologics, Lonza Cell & Gene Technologies, Thermo Fisher Scientific (Patheon / Brammer Bio), WuXi Advanced Therapies Unit, Charles River Laboratories and Catalent (Cell & Gene Therapy). Emerging players are Vineti and Cellares. Direct peers are AGC Biologics and Miltenyi Biotec.
Does BioCentriq have an API?
No public API is recorded for BioCentriq.
What industry is BioCentriq in?
BioCentriq's product category is Cell Therapy Contract Development & Manufacturing. Its primary akta.pro industry code is HLAGAGAA, Cell Therapy CDMO (Autologous/Allogeneic Manufacturing), with a secondary code of HLAGABAD, Cell Therapy CDMO. Its NAICS code is 3254 and its SIC code is 8731.